Year founded
1999
Country of origin
Belgium
HQ country
Belgium
Total deal value
Average deal value
Company industry
- Medical & Biotech
M&A expertise
- -
Industry expertise
- -
Galapagos is a clinical stage biotech company focused on developing novel medicines. Galapagos’ most advanced candidate drug GLPG0634 shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to Galapagos. With GLPG0634, Galapagos demonstrates its capabilities in developing novel medicines for difficult to cure diseases.
Latest deals
EcoR1 increases its stake in Galapagos
26-08-2024
Undisclosed
